CytoDyn (CYDY) Asset Writedowns and Impairment (2020 - 2022)

CytoDyn's Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $16.3 million for Q4 2022.

• Quarterly Asset Writedowns and Impairment rose 923.23% year-over-year to $16.3 million in Q4 2022, while the trailing twelve-month figure through May 2023 was $19.0 million (down 74.14% YoY) and the FY2023 annual result came in at $20.6 million, down 71.92% from the prior year.
• Asset Writedowns and Impairment was $16.3 million for Q4 2022 at CytoDyn, up from $2.7 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $64.6 million in Q2 2022 and bottomed at -$9.8 million in Q2 2021.
• A 3-year average of $10.8 million and a median of $4.8 million in 2020 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment tumbled 66.81% — and 2022, when it jumped 923.23%.
• CytoDyn's Asset Writedowns and Impairment stood at $4.8 million in 2020, then sank by 66.81% to $1.6 million in 2021, then soared by 923.23% to $16.3 million in 2022.
• Business Quant data shows CYDY's Asset Writedowns and Impairment at $16.3 million in Q4 2022, $2.7 million in Q3 2022, and $64.6 million in Q2 2022.